Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5275)
All Articles published online
|
Publishing Process of This Article
|
Aug 15, 2013 (publication date) through Dec 20, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Thompson CS. Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors. World J Diabetes 2013; 4(4): 124-129 [PMID: 23961322 DOI: 10.4239/wjd.v4.i4.124] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v4/i4/124.htm |
| Number | Citing Articles |
| 1 |
Yan Shang, Abubucker Peer Mohideen. Purpurin, a Natural Anthroquinone Ameliorates Streptozotocin-induced Diabetic Nephropathy via Attenuating Hyperglycemia, Dyslipidemia, and Inflammation in Rats. Pharmacognosy Magazine 2023; 19(2): 461 doi: 10.1177/09731296231158477
|
| 2 |
Qiang Jia, Rui Yang, Xiao‑Fen Liu, Shan‑Feng Ma, Lei Wang. Genistein attenuates renal fibrosis in streptozotocin‑induced diabetic rats. Molecular Medicine Reports 2018; doi: 10.3892/mmr.2018.9635
|
| 3 |
Yong-xian Shao, Manna Huang, Wenjun Cui, Ling-Jun Feng, Yinuo Wu, Yinghong Cai, Zhe Li, Xinhai Zhu, Peiqing Liu, Yiqian Wan, Hengming Ke, Hai-Bin Luo. Discovery of a Phosphodiesterase 9A Inhibitor as a Potential Hypoglycemic Agent. Journal of Medicinal Chemistry 2014; 57(24): 10304 doi: 10.1021/jm500836h
|
| 4 |
Linda S. Hoffmann, Christopher J. Larson, Alexander Pfeifer. Metabolic Control. Handbook of Experimental Pharmacology 2015; 233: 283 doi: 10.1007/164_2015_3
|
| 5 |
Mark McCarty. Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin—Potential for Preventing or Slowing the Progression of Diabetic Complications. Healthcare 2017; 5(1): 15 doi: 10.3390/healthcare5010015
|
| 6 |
Arif Ul Hasan, Wararat Kittikulsuth, Fuminori Yamaguchi, Tuba Musarrat Ansary, Asadur Rahman, Yuki Shibayama, Daisuke Nakano, Hirofumi Hitomi, Masaaki Tokuda, Akira Nishiyama. IBMX protects human proximal tubular epithelial cells from hypoxic stress through suppressing hypoxia-inducible factor-1α expression. Experimental Cell Research 2017; 358(2): 343 doi: 10.1016/j.yexcr.2017.07.007
|
| 7 |
N. Suganya, E. Bhakkiyalakshmi, D. V. L. Sarada, K. M. Ramkumar. Reversibility of endothelial dysfunction in diabetes: role of polyphenols. British Journal of Nutrition 2016; 116(2): 223 doi: 10.1017/S0007114516001884
|
| 8 |
Mark F. McCarty. In type 1 diabetics, high-dose biotin may compensate for low hepatic insulin exposure, promoting a more normal expression of glycolytic and gluconeogenic enyzymes and thereby aiding glycemic control. Medical Hypotheses 2016; 95: 45 doi: 10.1016/j.mehy.2016.08.002
|
| 9 |
Ryan Varghese, Gargi Digholkar, Jainam Karsiya, Sahil Salvi, Jeenam Shah, Dileep Kumar, Rohit Sharma. PDE5 inhibitors: breaking new grounds in the treatment of COVID-19. Drug Metabolism and Personalized Therapy 2024; 38(4): 295 doi: 10.1515/dmpt-2023-0011
|
| 10 |
Jingxue Han, Xinwei Wang, Jingyi Hou, Yu Liu, Peng Liu, Tingting Zhao, Kazim Husain. Using Network Pharmacology to Explore the Mechanism of Peach Kernel-Safflower in the Treatment of Diabetic Nephropathy. BioMed Research International 2021; 2021: 1 doi: 10.1155/2021/6642584
|
| 11 |
Ryan Varghese, Gargi Digholkar, Jainam Karsiya, Sahil Salvi, Jeenam Shah, Dileep Kumar, Rohit Sharma. PDE5 inhibitors: breaking new grounds in the treatment of COVID-19. Drug Metabolism and Personalized Therapy 2023; doi: 10.1515/dmdi-2023-0011
|